EISAI CO
🇯🇵Japan
- Country
- 🇯🇵Japan
- Ownership
- Public
- Established
- 1941-12-06
- Employees
- 11K
- Market Cap
- $12B
- Website
- http://www.eisai.co.jp
Post-Marketing Surveillance Study of Eribulin on the Status and Factors for the Development of Peripheral Neuropathy in Japan.
Completed
- Conditions
- Breast CancerHER2-negative Breast Cancer
- First Posted Date
- 2015-02-25
- Last Posted Date
- 2018-07-13
- Lead Sponsor
- Eisai Co., Ltd.
- Target Recruit Count
- 651
- Registration Number
- NCT02371174
A Post-Marketing Clinical Study of Aricept in Patients With Dementia With Lewy Bodies (DLB)
- First Posted Date
- 2015-01-26
- Last Posted Date
- 2019-01-08
- Lead Sponsor
- Eisai Co., Ltd.
- Target Recruit Count
- 160
- Registration Number
- NCT02345213
Post-Marketing Surveillance of Long-Term Observation of Gliadel Wafer-Investigation of Vital Prognosis in Patients With High Grade Glioma
Completed
- Conditions
- Malignant Glioma
- Interventions
- Other: No intervention
- First Posted Date
- 2014-11-25
- Last Posted Date
- 2018-11-05
- Lead Sponsor
- Eisai Co., Ltd.
- Target Recruit Count
- 507
- Registration Number
- NCT02300506
Post-Marketing Surveillance of Gliadel 7.7mg Implant (All-case Observational Study)
Completed
- Conditions
- Malignant Glioma
- Interventions
- Other: No intervention
- First Posted Date
- 2014-11-25
- Last Posted Date
- 2017-02-27
- Lead Sponsor
- Eisai Co., Ltd.
- Target Recruit Count
- 561
- Registration Number
- NCT02300532
A Study to Assess Safety, Tolerability, and Pharmacokinetics of E2307 in Healthy Young and Elderly Japanese Subjects
- First Posted Date
- 2014-11-13
- Last Posted Date
- 2016-01-18
- Lead Sponsor
- Eisai Co., Ltd.
- Target Recruit Count
- 24
- Registration Number
- NCT02289599
Phase 1 Study of E7090 in Subjects With Solid Tumor
- First Posted Date
- 2014-10-27
- Last Posted Date
- 2021-09-28
- Lead Sponsor
- Eisai Co., Ltd.
- Target Recruit Count
- 40
- Registration Number
- NCT02275910
- Locations
- 🇯🇵
Eisai Trial Site #1, Osaka, Japan
🇯🇵Eisai Trial Site #3, Osaka, Japan
🇯🇵Eisai Trial Site #2, Osaka, Japan
Post-marketing Surveillance of DC Bead in Patients With Hepatocellular Carcinoma
Completed
- Conditions
- Hepatocellular Carcinoma
- Interventions
- Device: E7040
- First Posted Date
- 2014-10-21
- Last Posted Date
- 2018-11-05
- Lead Sponsor
- Eisai Co., Ltd.
- Target Recruit Count
- 300
- Registration Number
- NCT02269995
Single/ Multiple-Dose Study of E6007 in Healthy Japanese Male Subjects
- First Posted Date
- 2014-10-20
- Last Posted Date
- 2016-01-20
- Lead Sponsor
- Eisai Co., Ltd.
- Target Recruit Count
- 24
- Registration Number
- NCT02268838
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Once-daily Oral Avatrombopag in Japanese Subjects With Chronic Liver Diseases and Thrombocytopenia
Phase 2
Completed
- Conditions
- Thrombocytopenia Associated With Chronic Liver Disease
- Interventions
- Drug: Placebo
- First Posted Date
- 2014-08-28
- Last Posted Date
- 2019-02-28
- Lead Sponsor
- Eisai Co., Ltd.
- Target Recruit Count
- 39
- Registration Number
- NCT02227693
Eribulin Versus Vinorelbine in Subjects With Locally Recurrent or Metastatic Breast Cancer Previously Treated With Anthracyclines and Taxanes
Phase 3
Completed
- Conditions
- Breast CancerBreast TumorsHER2-Negative Breast CancerTriple Negative Breast CancerCancer of Breast
- Interventions
- Drug: E7389 (Eribulin Mesylate)
- First Posted Date
- 2014-08-26
- Last Posted Date
- 2018-08-28
- Lead Sponsor
- Eisai Co., Ltd.
- Target Recruit Count
- 530
- Registration Number
- NCT02225470
- Locations
- 🇨🇳
33 Eisai Trial Site, Beijing, Beijing, China
🇨🇳10 Eisai Trial Site, Nanning, Guangxi, China
🇨🇳20 Eisai Trial Site, Guangzhou, Guangdong, China